Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

Alligators_in_the_Sewer Jun. 24 at 11:51 PM

$CUE https://lifesciencereport.com/news/nasdaq/cue/cue-biopharma-receives-fda-feedback-on-pre-ind-briefing-document-reinforcing-company-s-intention-to-advance-ind-submission-for-cue-401-to-address-unmet-need-in-the-treatment-of-autoimmune-disease Only 12 years until FDA approval for 401! @TotalAmateur @InvestingDoc @ES33 @Mastersushie1 @spylock

0 · Reply

Alligators_in_the_Sewer Jun. 16 at 6:32 PM

$CUE CFO resigning is a clear indicator nothing special is happening for a long while, if ever @TotalAmateur @InvestingDoc

0 · Reply

Invest2live Jun. 12 at 3:15 PM

$HCTI 446% already; congrats 🎊🎈🎉 Check out; $GOSS and $CUE

1 · Reply

Invest2live Jun. 11 at 2:51 PM

$CUE signs of growth; do your DD and get in.

0 · Reply

DonCorleone77 Jun. 10 at 8:18 PM

$CUE Cue Biopharma CFO resigns, CEO to be interim principal financial officer In a regulatory filing, Cue Biopharma disclosed that on June 4, Kerri-Ann Millar notified the company that she is resigning from her position as Chief Financial Officer, effective June 13. Effective June 13, Daniel Passeri, the company's Chief Executive Officer, will serve as the company's principal financial and accounting officer on an interim basis until a new principal financial and accounting officer is designated, the filing stated.

1 · Reply

Alligators_in_the_Sewer Jun. 9 at 5:23 PM

$CUE seems as though the story here has ended

0 · Reply

NotoriousSixtyTwo Jun. 6 at 3:49 PM

$CUE Any upcoming catalysts or reason for hope here? Big bag-holder here.

1 · Reply

PMdungbeetle Jun. 6 at 11:48 AM

$CHTR $CUE $KOPN $MLSS $REFR can I tell you all to buy big volumes of these dogshit stocks so it goes up pennies and I can sell to get out? I let you know that I sold when you find out!

1 · Reply

PMdungbeetle Jun. 3 at 4:59 PM

$CHTR $CUE $KOPN $MLSS $REFR a C post from the past! Still holds true!!

1 · Reply

Relee187200 May. 22 at 1:23 PM

$CUE Pathetic

0 · Reply

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 12, 2025, 4:05 PM EDT - 6 weeks ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 6 weeks ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 7 weeks ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 6:12 PM EDT - 2 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 2:00 AM EDT - 2 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 2 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:05 PM EDT - 2 months ago

Cue Biopharma Announces Proposed Public Offering

Apr 14, 2025, 5:02 PM EDT - 2 months ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 3 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Nov 29, 2024, 4:30 PM EST - 7 months ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 7 months ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 7 months ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 7 months ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 8 months ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 9 months ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 9 months ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 9 months ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 10 months ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 8:17 PM EDT - 11 months ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 4:05 PM EDT - 11 months ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 1 year ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 11, 2023, 3:32 PM EST - 1 year ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Mar 21, 2023, 11:00 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Feb 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

Feb 16, 2023, 10:30 AM EST - 2 years ago

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Feb 16, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

Feb 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two February 2023 Scientific Conferences

Jan 23, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Announces Chief Medical Officer Transition

Nov 14, 2022, 11:23 PM EST - 2 years ago

Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Call Transcript

Alligators_in_the_Sewer Jun. 24 at 11:51 PM

0 · Reply

Alligators_in_the_Sewer Jun. 16 at 6:32 PM

$CUE CFO resigning is a clear indicator nothing special is happening for a long while, if ever @TotalAmateur @InvestingDoc

0 · Reply

Invest2live Jun. 12 at 3:15 PM

$HCTI 446% already; congrats 🎊🎈🎉 Check out; $GOSS and $CUE

1 · Reply

Invest2live Jun. 11 at 2:51 PM

$CUE signs of growth; do your DD and get in.

0 · Reply

DonCorleone77 Jun. 10 at 8:18 PM

1 · Reply

Alligators_in_the_Sewer Jun. 9 at 5:23 PM

$CUE seems as though the story here has ended

0 · Reply

NotoriousSixtyTwo Jun. 6 at 3:49 PM

$CUE Any upcoming catalysts or reason for hope here? Big bag-holder here.

1 · Reply

PMdungbeetle Jun. 6 at 11:48 AM

$CHTR $CUE $KOPN $MLSS $REFR can I tell you all to buy big volumes of these dogshit stocks so it goes up pennies and I can sell to get out? I let you know that I sold when you find out!

1 · Reply

PMdungbeetle Jun. 3 at 4:59 PM

$CHTR $CUE $KOPN $MLSS $REFR a C post from the past! Still holds true!!

1 · Reply

Relee187200 May. 22 at 1:23 PM

$CUE Pathetic

0 · Reply

PenkeTrading May. 22 at 9:07 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Cue Biopharma. Is that bullish or bearish? $CUE #RsiOversold #NASDAQ

0 · Reply

TotalAmateur May. 20 at 2:15 PM

$CUE I guess what's been said is all there is to say for now. I'm guessing the share price will bleed out for the remainder of 2025, and that may be the time to buy back for a long term hold below 50cents. See you guys down the road.

1 · Reply

Alligators_in_the_Sewer May. 14 at 6:55 PM

$CUE webcast is tomorrow, will CUE finally announce something material that will increase shareholder value? @InvestingDoc @TotalAmateur

1 · Reply

GlynnBusson May. 13 at 3:39 PM

$CUE so disappointed in Cue execution and so disappointed in management. Stock held a lot of promise once.

0 · Reply

Alligators_in_the_Sewer May. 9 at 7:53 PM

$CUE @ES33 you remain the sole bull on CUE. Can you comment on why you remain optimistic?

0 · Reply

ES33 May. 7 at 4:21 PM

$CUE Virtual Investor Event - May 15th 11AM ET https://lifescievents.com/event/cue/

2 · Reply

Alligators_in_the_Sewer Apr. 30 at 5:02 PM

$CUE I see no distinct reason to hold any longer.

0 · Reply

PMdungbeetle Apr. 29 at 12:07 PM

$MLSS hmmm…. Should I buy more of this, or ADIL, or SEED, or SKYX, or $CUE, or $CHTR, or CRNT, or $REFR, or $KOPN….? …, I have so so many losers to choose from, I don’t know where to begin!

6 · Reply

PMdungbeetle Apr. 26 at 8:43 PM

$CUE pew pew pew cue

1 · Reply

PMdungbeetle Apr. 24 at 11:56 PM

$CUE P. U. To CUE!!!! Nothing as stinky as this one!!

0 · Reply

Alligators_in_the_Sewer Apr. 22 at 3:54 PM

$CUE

0 · Reply

JFDI Apr. 21 at 2:39 PM

Ahhhhh man, $CUE up that $XBI $XLE $DUOL. How this gonna shake out. (ps, im stuck in the middle with you)

1 · Reply

Market Cap	49.35M
Revenue (ttm)	9.29M
Net Income (ttm)	-40.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-437.78%
Debt to Equity Ratio	0.51

Volume	1,005,100
Avg Vol	203,496
Day's Range	N/A - N/A
Shares Out	75.35M
Stochastic %K	94%
Beta	1.42
Analysts	Strong Sell
Price Target	$4.00